SOURCE-LINKED INTELLIGENCE
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.
The DCM-NEXT consortium combines world-leading interdisciplinary expertise and resources of 8 investigators in the fields of DCM, deep clinical phenotyping, cardiogenomics, cardiac transcriptomics, artificial intelligence, in silico drug target discovery and functional studies. They will uniquely leverage their unparalleled cohort of 11,750 DCM probands and relatives with extensive clinical and omics data. Through cutting-edge genomic and cardiac transcriptomic studies, the project aims to (1) revolutionise genetic testing and patient stratification for more precise prediction of disease onset, progression and risk of major adverse cardiac events; and (2) accelerate development of novel therapies by identifying and validating targets involved in pathogenesis of DCM. Dilated cardiomyopathy, Single cell transcriptomics
Read original source ↗ Open in workspace
- recordType
- award
- status
- SIGNED
- region
- EU
- value
- 4137668.75
- unit
- EUR
Evidence & attribution
European Commission, CORDIS Horizon Europe project dataset. Metadata adapted.
License: CORDIS reuse policy
First collected: 2026-09-20T01:21:06.728Z. This is not the publication date.